Cytochrome P450 enzymes and genotype-guided drug therapy

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 6, 2009, Pages 632-640

  Roederer, Mary W ^a  

^a University of North Carolina   (United States)

Author keywords

CYP2C8; CYP2C9; CYP2D6; Genotype guided dosing; Pharmacogenetic; Tamoxifen; Warfarin

Indexed keywords

AMODIAQUINE; ANASTROZOLE; CYTOCHROME P450; CYTOCHROME P450 2C8; LETROZOLE; TAMOXIFEN; WARFARIN;

ALLELE; BLOOD CLOTTING DISORDER; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; DIAGNOSTIC TEST; ENZYME ACTIVITY; GENOTYPE; HEREDITY; HUMAN; MALARIA; PHENOTYPE; REVIEW; SENSITIVITY AND SPECIFICITY;

AMODIAQUINE; ANTICOAGULANTS; ANTIMALARIALS; BREAST NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; ESTROGEN ANTAGONISTS; FEMALE; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; ISOENZYMES; MALARIA; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; TAMOXIFEN; WARFARIN; XENOBIOTICS;

EID: 72449173439     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther (2007) 116(3):496-526.
2. Zanger UM, Turpeinen M, Klein K, Schwab M: Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem (2008) 392(6):1093-1108.
3. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW: Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternativesplice variants. Pharmacogenetics (2004) 14(1):1-18.
4. Human Cytochrome P450 (CYP) Allele Nomenclature Committee homepage: Human Cytochrome P450 (CYP) Allele Nomenclature Committee (2008). www.cypalleles.ki.se/
5. Omura T, Sato R: A new cytochrome in liver microsomes. J Biol Chem (1962) 237:1375-1376.
6. Global burden of disease report 2004: WHO, Geneva, Switzerland (2004). www.who.int/healthinfo/global-burden-disease/GBD-report-2004update-full.pdf
7. Clinical practice guidelines in oncology: National Comprehensive Cancer Network, Fort Washington, PA, USA (2008). www.nccn.org/ professionals/physician- gls/f-guidelines.asp
8. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer: NICE, London, UK (2006). guidance.nice.org.uk/TA112
9. International Breast Cancer Study Group, Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD: Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol (2006) 24(9):1332-1341. (Pubitemid 46621995)
10. Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, Margolese RG, Nesbitt L, Paik S, Pisansky TM, Wolmark N: Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol (2002) 20(20):4141-4149.
11. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD et al: Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst (2005) 97(22):1652-1662. (Pubitemid 41672231)
12. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgen SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM et al: The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2007) 101(1):113-121.
13. Essential Medicines Library: WHO, Geneva, Switzerland (2007). www.who.int/emlib/MedicineDisplay.aspx?Language=EN&MedID Name=260%40praziquantel
14. Desta Z, Ward BA, Soukhova NV, Flockhart DA: Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 310(3): 1062-1075.
15. Borgna JL, Rochefort H: Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J Biol Chem (1981) 256(2):859-868.
16. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G et al: Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 80(1):61-74.
17. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC: Pharmacological characterization of 4-hydroxy-N- desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat (2004) 85(2):151-159.
18. Lim YC, Li L, Desta Z, Zhao Q, Rae JM, Flockhart DA, Skaar TC: Endoxifen, a secondary metabolite of tamoxifen, and 4-OHtamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther (2006) 318(2):503-512.
19. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 95(23):1758-1764.
20. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R et al: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 97(1):30-39.
21. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, Stuven T, Eichelbaum M: Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics (1998) 8(1):15-26.
22. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol (2007) 25(33):5187-5193.
23. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet (2002) 359(9324):2131-2139.
24. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med (2004) 350(11):1081-1092. (Pubitemid 38298988)
25. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 349(19):1793-1802.
26. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol (2005) 23(3):619-629.
27. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer (2003) 98(9):1802-1810.
28. Buijs C, De Vries EG, Mourits MJ, Willemse PH: The influence of endocrine treatments for breast cancer on health-related quality of life. Cancer Treat Rev (2008) 34(7):640-655.
29. Global burden of malaria: UN Millennium Project, New York City, NY, USA (2005). www.unmillenniumproject.org/documents/ GlobalBurdenofMalaria.pdf
30. Guidelines for the treatment of malaria: WHO, Geneva, Switzerland (2006). apps.who.int/malaria/docs/TreatmentGuidelines2006.pdf
31. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N, International Artemisnin Study Group: Artesunate combinations for treatment of malaria: Meta-analysis. Lancet (2004) 363(9402):9-17.
32. Olliaro P, Mussano P: Amodiaquine for treating malaria. Cochrane Database Syst Rev (2003) (2):CD000016.
33. Phillips-Howard PA, West LJ: Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med (1990) 83(2):82-85.
34. Naisbitt DJ, Williams DP, O'Neill PM, Maggs JL, Willock DJ, Pirmohamed M, Park BK: Metabolism-dependent neutrophil cytotoxicity of amodiaquine: A comparison with pyronaridine and related antimalarial drugs. Chem Res Toxicol (1998) 11(12):1586-1595.
35. Li XQ, Björkman A, Andersson TB, Ridderström M, Masimirembwa CM: Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: A new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther (2002) 300(2):399-407.
36. Churchill FC, Patchen LC, Campbell CC, Schwartz IK, Nguyen-Dinh P, Dickinson CM: Amodiaquine as a prodrug: Importance of metabolite(s) in the antimalarial effect of amodiaquine in humans. Life Sci (1985) 36(1):53-62.
37. Jewell H, Maggs JL, Harrison AC, O'Neill PM, Ruscoe JE, Park BK: Role of hepatic metabolism in the bioactivation and detoxication of amodiaquine. Xenobiotica (1995) 25(2):199-217.
38. Harrison AC, Kitteringham NR, Clarke JB, Park BK: The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem Pharmacol (1992) 43(7):1421-1430.
39. Clarke JB, Maggs JL, Kitteringham NR, Park BK: Immunogenicity of amodiaquine in the rat. Int Arch Allergy Appl Immunol (1990) 91(4):335-342.
40. Clarke JB, Neftel K, Kitteringham NR, Park BK: Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. Int Arch Allergy Appl Immunol (1991) 95(4):369-375.
41. Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL: Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: Implications for malaria treatment in Africa. Clin Pharmacol Ther (2007) 82(2):197-203.
42. Cavaco I, Strömberg-Nörklit J, Kaneko A, Msellem MI, Dahoma M, Ribeiro VL, Bjorkman A, Gil JP: CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol (2005) 61(1):15-18.
43. Gil JP: Amodiaquine pharmacogenetics. Pharmacogenomics (2008) 9(10):1385-1390.
44. Wysowski DK, Nourjah P, Swartz L: Bleeding complications with warfarin use: A prevalent adverse effect resulting in regulatory action. Arch Intern Med (2007) 167(13):1414-1419.
45. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther (2006) 79(4):291-302.
46. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF: Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol (1992) 5(1):54-59.
47. Lee CR, Goldstein JA, Pieper JA: Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data. Pharmacogenetics (2002) 12(3):251-263.
48. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J Am Med Assoc (2002) 287(13):1690-1698.
49. McClain MR, Palomaki GE, Piper M, Haddow JE: A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med (2008) 10(2): 89-98.
50. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD et al: Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 360(8):753-764.
51. WarfarinDosing.org: Barnes-Jewish Hospital at Washington University, St Louis, MO, USA (2009). www.warfarindosing.org
52. Garcia DA, Hylek E: Warfarin pharmacogenetics. N Engl J Med (2009) 360(23):2474; author reply 2475.
53. Marsh S, Van Booven DJ, McLeod HL: Global pharmacogenetics: Giving the genome to the masses. Pharmacogenomics (2006) 7(4):625-631.
54. Shin J, Kayser SR: Clinical pharmacy consultation for pharmacogenetic testing. Per Med (2009) 6(2):183-192.
55. No authors listed: News & views in pharmacogenomics. Pharmacogenomics (2009) 10(5):715-717.
56. Leeder JS, Pearce RE, Gaedigk A, Modak A, Rosen DI: Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype. J Clin Pharmacol (2008) 48(9):1041-1051.
57. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM: Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol (2003) 59 (5-6):429-442.
58. Tingle MD, Jewell H, Maggs JL, O'Neill PM, Park BK: The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro: Chemical mechanisms and the effects of fluorine substitution. Biochem Pharmacol (1995) 50(7): 1113-1119.
59. Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, Hewett M, Lin Z, Liu Y, Liu S, Oliver DR, Rubin DL et al: Intergrating genotype and phenotype information: An overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J (2001) 1(3):167-170.
60. Warfarin pathway pharmacokinetics: PharmGKB, Stanford University, Stanford, CA, USA (2009). www.pharmgkb.org/do/serve? objId= PA145011113&objCls=Pathway
61. Wadelius M, Sörlin K, Wallerman O, Karlsson J, Yue QY, Magnusson PK, Wadelius C, Melhus H: Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J (2004) 4(1):40-48.